Emma Handley1, Caroline H Nicolson2, Mark Hew2, Annemarie L Lee3. 1. Alfred Health Hospital Admission Risk Program - Pulmonary Rehabilitation, Caulfield Hospital, Caulfield, Victoria, Australia. 2. Department of Allergy, Immunology and Respiratory Medicine, Alfred Health, Melbourne, Victoria, Australia. 3. Department of Physiotherapy, School of Primary and Allied Health Care, Monash University, Frankston, Victoria, Australia; Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia; Physiotherapy, Rehabilitation, Nutrition and Sport, La Trobe University, Bundoora, Victoria, Australia. Electronic address: Annemarie.Lee@monash.edu.
Abstract
BACKGROUND: Chronic rhinosinusitis (CRS) is an extrapulmonary manifestation in some individuals with bronchiectasis, but the prevalence of CRS in this population and its clinical impact has not been systematically reviewed. OBJECTIVE: To systematically review the prevalence of CRS in bronchiectasis and identify its clinical implications. METHODS: Four databases were searched from inception to August 2018 for studies reporting the prevalence and/or clinical impact of CRS in individuals with bronchiectasis. Clinical outcomes included health-related quality of life (HRQOL), severity of bronchiectasis, lung function, clinical and psychological symptoms, exacerbation frequency, and health care utilization. Two independent reviewers rated the quality of evidence using the risk of bias for prevalence trials tool. RESULTS: Of 80 studies identified, 8 studies with 797 participants (all adults) were included. Mean FEV1 % predicted was 77.7%. Overall, 5 studies were classed as low risk of bias and 3 were of moderate risk of bias. The pooled prevalence of clinical and/or radiological CRS was 62% (95% CI, 50%-74%). CRS was associated with a greater degree of bronchiectasis severity, poorer HRQOL, reduction in smell detection, elevated levels of inflammatory markers, and reduced time to first exacerbation. However, the association with airflow obstruction was inconsistent and there was no impact on anxiety or depression. CONCLUSIONS: CRS is present in 62% of adults with bronchiectasis. Its presence is associated with poorer HRQOL, greater degree of disease severity, and more extensive radiological bronchiectasis.
BACKGROUND:Chronic rhinosinusitis (CRS) is an extrapulmonary manifestation in some individuals with bronchiectasis, but the prevalence of CRS in this population and its clinical impact has not been systematically reviewed. OBJECTIVE: To systematically review the prevalence of CRS in bronchiectasis and identify its clinical implications. METHODS: Four databases were searched from inception to August 2018 for studies reporting the prevalence and/or clinical impact of CRS in individuals with bronchiectasis. Clinical outcomes included health-related quality of life (HRQOL), severity of bronchiectasis, lung function, clinical and psychological symptoms, exacerbation frequency, and health care utilization. Two independent reviewers rated the quality of evidence using the risk of bias for prevalence trials tool. RESULTS: Of 80 studies identified, 8 studies with 797 participants (all adults) were included. Mean FEV1 % predicted was 77.7%. Overall, 5 studies were classed as low risk of bias and 3 were of moderate risk of bias. The pooled prevalence of clinical and/or radiological CRS was 62% (95% CI, 50%-74%). CRS was associated with a greater degree of bronchiectasis severity, poorer HRQOL, reduction in smell detection, elevated levels of inflammatory markers, and reduced time to first exacerbation. However, the association with airflow obstruction was inconsistent and there was no impact on anxiety or depression. CONCLUSIONS:CRS is present in 62% of adults with bronchiectasis. Its presence is associated with poorer HRQOL, greater degree of disease severity, and more extensive radiological bronchiectasis.
Authors: Brian S Schwartz; Saba A Al-Sayouri; Jonathan S Pollak; Annemarie G Hirsch; Robert Kern; Bruce Tan; Atsushi Kato; Robert P Schleimer; Anju T Peters Journal: J Allergy Clin Immunol Date: 2022-03-18 Impact factor: 14.290
Authors: Shaan N Somani; Jason H Kwah; Chen Yeh; David B Conley; Leslie C Grammer; Robert C Kern; Michelle Prickett; Robert P Schleimer; Stephanie S Smith; Whitney W Stevens; Bruce K Tan; Kevin C Welch; Anju T Peters Journal: Int Forum Allergy Rhinol Date: 2019-10-07 Impact factor: 3.858
Authors: Annemarie L Lee; Caroline H H Nicolson; Janet Bondarenko; Brenda M Button; Samantha Ellis; Robert G Stirling; Mark Hew Journal: Immun Inflamm Dis Date: 2021-10-14